TABLE 1.

Baseline Characteristics Among the First Targeted Therapy Cohorts Before and After Propensity Score Matching

	Before Matchinga			After Matchingb
	Pazopanib n = 526	Sunitinib n = 1,185	P Value	Pazopanib n = 522	Sunitinib n = 522	P Value
Demographics at index date
Age, years, mean ± SD	74.8 ± 6.0	74.7 ± 5.9	0.733	74.8 ± 6.0	75.2 ± 6.3	0.354
Male, n (%)	307 (58.4)	682 (57.6)	0.754	305 (58.4)	303 (58.0)	0.900
Race, n (%)
White	463 (88.0)	993 (83.8)	0.024c	459 (87.9)	460 (88.1)	0.917
Black	29 (5.5)	85 (7.2)	0.204	29 (5.6)	25 (4.8)	0.572
Other or unknown	34 (6.5)	107 (9.0)	0.075	34 (6.5)	37 (7.1)	0.705
Follow-up duration after index date, months, mean ± SD	15.7 ± 10.7	17.2 ± 13.7	0.570	15.7 ± 10.7	15.7 ± 12.5	0.919
Year of RCC diagnosis, n (%)
2006-2009	203 (38.6)	548 (46.2)	0.003c	202 (38.7)	200 (38.3)	0.888
2010-2014	323 (61.4)	637 (53.8)	0.003c	320 (61.3)	322 (61.7)	0.888
Metastatic sites, n (%)
Lung	298 (56.7)	596 (50.3)	0.015c	294 (56.3)	280 (53.6)	0.358
Lymph node	102 (19.4)	187 (15.8)	0.066	100 (19.2)	102 (19.5)	0.876
Bone	168 (31.9)	405 (34.2)	0.365	167 (32.0)	171 (32.8)	0.792
Liver	75 (14.3)	175 (14.8)	0.783	75 (14.4)	76 (14.6)	0.931
CCI, mean ± SD	9.2 ± 2.4	9.2 ± 2.4	0.811	9.2 ± 2.4	9.2 ± 2.4	0.956
Comorbidities, n (%)
Cardiovascular disease	343 (65.2)	737 (62.2)	0.233	341 (65.3)	338 (64.8)	0.842
Hypertension	474 (90.1)	1,072 (90.5)	0.821	470 (90.0)	471 (90.2)	0.916
Chronic pulmonary disease	181 (34.4)	438 (37.0)	0.311	181 (34.7)	177 (33.9)	0.791
Diabetes	227 (43.2)	569 (48.0)	0.063	227 (43.5)	223 (42.7)	0.797
Renal failure	248 (47.1)	547 (46.2)	0.705	246 (47.1)	264 (50.6)	0.279
Liver disease	27 (5.1)	78 (6.6)	0.249	27 (5.2)	19 (3.6)	0.228
Monthly per patient health care resource use, mean ± SD
Inpatient admissions	0.086 ± 0.105	0.088 ± 0.097	0.244	0.086 ± 0.105	0.094 ± 0.095	0.120
Inpatient days	0.591 ± 0.898	0.630 ± 0.925	0.163	0.593 ± 0.901	0.653 ± 0.843	0.214
Inpatient readmissions	0.014 ± 0.051	0.016 ± 0.047	0.141	0.014 ± 0.051	0.016 ± 0.046	0.321
Emergency room visits	0.048 ± 0.079	0.053 ± 0.110	0.609	0.049 ± 0.079	0.049 ± 0.085	0.892
Outpatient visits	0.888 ± 0.681	0.847 ± 0.874	0.012c	0.879 ± 0.672	0.912 ± 1.045	0.420
Monthly per patient health care costs to the payer (2015 USD), mean ± SD
Total all-cause health care costs	3,005 ± 3,133	2,952 ± 3,074	0.797	2,998 ± 3,142	3,114 ± 2,792	0.244
Total all-cause medical costs	2,862 ± 3,081	2,791 ± 3,035	0.968	2,855 ± 3,090	2,960 ± 2,747	0.243
Inpatient costs	1,629 ± 2,498	1,601 ± 2,355	0.394	1,633 ± 2,506	1,700 ± 2,194	0.290
Emergency room costs	37 ± 76	43 ± 103	0.631	37 ± 76	39 ± 80	0.927
Outpatient costs	404 ± 414	344 ± 395	< 0.001c	393 ± 369	388 ± 448	0.146
Skilled nursing facility costs	117 ± 497	146 ± 604	0.258	118 ± 499	138 ± 557	0.577
Home health agency costs	106 ± 264	100 ± 265	0.581	106 ± 265	103 ± 256	0.884
Other medical service costs	569 ± 723	557 ± 784	0.459	568 ± 723	593 ± 798	0.700
Total all-cause pharmacy costs	143 ± 261	161 ± 324	0.004c	143 ± 262	154 ± 311	0.108

^aBefore matching, Wilcoxon rank-sum tests were used for continuous variables, and chi-square tests were used for categorical variables.

^bAfter matching, Wilcoxon signed-rank tests were used for continuous variables, and McNemar tests were used for categorical variables.

^cP < 0.05 for pairwise comparison of the pazopanib cohort with the sunitinib cohort.

CCI = Charlson Comorbidity Index; RCC = renal cell carcinoma; SD = standard deviation; USD = U.S. dollars.